Kompendium 2021 Forschung & Klinik

Comparative 3 Year
ACTIS Stem data
Survival analysis for all-cause
revision following primary total hip
arthroplasty with a medial collared,
triple-tapered primary hip stem versus
other implants in real-world settings.
Chitnis A, Mantel J, Ruppenkamp J, Bourcet A, Holy C
Current Medical Research Opinion. 2020 Sep 22:1-7.
• A retrospective cohort study identified 1,213 patients who received the
ACTIS Total Hip. This group was compared to 6,916 patients who
received other THA implants.
• Data was drawn from the Mercy Healthcare Systems Orthopedics
Database, a large US based multi-state database.
• Kaplan-Meier survival curves were generated, and a multivariable
Cox proportional hazard model was used to compare the relative risk
of revision.
57% lower risk of revisions
Adjusted Hazard Ratio 0.43 ((0.19-0.97) p=0.042)
3
ACTIS Stem revision rate estimated
at 1.08% at years 2 and 3
2.63%
(2.19%-3.16%)
2
1.9%
(1.57%-2.29%)
2.29%
(1.91%-2.74%)
2.63%
(2.19%-3.16%)
1.08%
(0.43%-2.72%)
ALL-CAUSE REVISION RATE AT 3 YEARS
1
0
0.64%
(0.28%-1.43%)
1.08%
(0.43%-2.72%)
1.08%
(0.43%-2.72%)
YR 1 YR 2 YR 3
ACTIS STEM
OTHER THA IMPLANTS
57% Reduced Risk of Revision when
Compared to Other THA Implants
Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.
Johnson & Johnson Medical Limited. Baird House, 4 Lower Gilmore Bank, Edinburgh, EH3 9QP, United Kingdom.
Incorporated and registered in Scotland under company number SC132162.
www.jnjmedicaldevices.com
© DePuy Synthes 2020. All Rights Reserved.
155950-201015 DSUS/EMEA